AbbVie stock: USD 1.37 billion IBD license expands pipeline
Published on 11/06/2026 at 17:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline Deal Adds Immunology Optionality
- AbbVie secured worldwide development and commercial rights to an investigational oral treatment for inflammatory bowel disease.
- The program remains early stage, leaving clinical progress, regulatory filings and efficacy data as the next investor milestones.
- The agreement adds a potential asset as AbbVie works to sustain growth after Stelara lost market exclusivity.
AbbVie has secured exclusive worldwide rights to develop and commercialize Nxera Pharma's investigational NXE0033744 for inflammatory bowel disease. According to Ad-hoc News, the agreement reported on Friday, November 6, 2026, gives AbbVie another potential immunology asset.
New Asset Remains Investigational
AbbVie will pay Nxera Pharma USD 100 million upfront, while the Japanese drugmaker can receive up to USD 1.37 billion in development and commercial milestone payments. The agreement also includes royalties, but the reported terms do not specify the rates or a closing date.
NXE0033744 is an oral small-molecule EP4 receptor agonist designed for gut-selective anti-inflammatory activity. A Phase I study showed gut selectivity and target engagement, but the candidate still depends on further clinical development, regulatory progress and market acceptance.
Pipeline Progress Sets Next Tests
The license broadens AbbVie's inflammatory-disease portfolio as Skyrizi remains a key growth driver and the company manages the loss of market exclusivity for Stelara. The next relevant signals are the timing and design of further clinical work, efficacy results in inflammatory bowel disease and any regulatory filings. No Phase II start date or clinical response rate was provided in the reported agreement.
The real-time quote of AbbVie stock put AbbVie stock at 259.10 euros on Lang & Schwarz at 17:02 CET on Friday, November 6, 2026, 1.41 percent below the Xetra close of Thursday, November 5, and 1.65 percent above the 254.90 euros quoted at 12:37 CET in the previous report.
AbbVie Inc. stock facts
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Xetra ticker: 4AB.DE
- Sector: Healthcare
- Lang & Schwarz price: 259.10 euros at 17:02 CET on November 6, 2026
- Change versus Xetra close: 1.41 percent below 262.80 euros on November 5, 2026
- 52-week Xetra range: 162.85 to 270.70 euros
US pharmaceutical shares remain sensitive to clinical catalysts, pricing pressure and broader risk appetite. Investors can follow the S&P 500 market environment alongside company-specific pipeline developments.
More news and analyses on AbbVie stock will track clinical, regulatory and commercial developments.
